Losartan reduces mortality in a genetic model of heart failure-Reference-Cited by-同舟云学术

Losartan reduces mortality in a genetic model of heart failure

Published:2010-08-10 Issue:3 Volume:382 Page:265-278
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmied Arch Pharmacol

Author:

Günther Sophie,Baba Hideo A.,Hauptmann Steffen,Holzhausen Hans-Jürgen,Großmann Claudia,Punkt Karla,Kusche Tina,Jones Larry R.,Gergs Ulrich,Neumann Joachim

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00210-010-0544-3.pdf

Reference50 articles.

1. Alpert N, Gordon M (1962) Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol 20:940–946

2. Baba HA, Iwai T, Bauer M, Irlbeck M, Schmid KW, Zimmer HG (1999) Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. J Mol Cell Cardiol 31:445–455

3. Cho MC, Rapacciuolo A, Koch WJ, Kobayashi Y, Jones LR, Rockman HA (1999) Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem 274:22251–22256

4. Crozier I, Ikram H, Awan N, Cleland Z, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Ruscinska E (1995) Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 91:691–697

5. Daul A, Elter-Schulz M, Poller U, Jockenhovel F, Pönicke K, Boomsma F, Man in’t Veld AJ, Schäfers RF, Brodde OE (1995) Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 352:429–437

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model;PLOS ONE;2018-08-09

2. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease;Pharmacology & Therapeutics;2016-08

3. AT1 receptor blocker azilsartan medoxomil normalizes plasma miR-146a and miR-342-3p in a murine heart failure model;Biomarkers;2016-07-11

4. The Therapeutic Effect of 2-Cyclohexylthio-AMP in Heart Failure;Journal of Cardiovascular Pharmacology;2013-06

5. Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways;Naunyn-Schmiedeberg's Archives of Pharmacology;2013-04-28